Mohapel · Neuroscience 2005 · controlled animal experiment · n=?

Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions.

Cited 161 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal research (rodent model)

PubMed 15837137 · doi:10.1016/j.neuroscience.2004.11.056 · record verified 2026-08-29

What was done

Adult rats with unilateral 6-hydroxydopamine (6-OHDA) lesions received 10-day intracerebroventricular infusions of either platelet-derived growth factor (PDGF-BB) or brain-derived neurotrophic factor (BDNF). Cell genesis was measured by bromodeoxyuridine (BrdU) incorporation. Three weeks after treatment cessation, brain tissue was evaluated immunohistochemically for markers of neurogenesis and lineage differentiation, including NeuN, doublecortin, Pbx (early striatal marker), DARPP-32 (mature striatal projection neuron marker), and tyrosine hydroxylase (dopaminergic marker) in the striatum and substantia nigra.

What was found

The abstract does not provide exact numerical counts or effect sizes. Both growth factors increased BrdU-labeled newly formed cells in the striatum and substantia nigra to an equal extent after 10 days. At 3 weeks post-treatment, there was a significant increase in BrdU+/NeuN+ striatal neurons and numerous doublecortin-positive neuroblasts in the denervated striatum. A subset of new striatal neurons expressed Pbx. However, no BrdU-labeled cells co-expressed DARPP-32 or tyrosine hydroxylase in either the striatum or substantia nigra.

Why it matters

This demonstrates that PDGF-BB and BDNF can stimulate endogenous neuroblast recruitment and early neuronal differentiation in a Parkinsonian brain environment. However, the lack of dopaminergic or mature projection neuron differentiation highlights major biological hurdles for endogenous cell replacement strategies.

Limits

This is an animal study in a toxin-induced Parkinson's model, which may not replicate human disease pathology. The abstract omits sample sizes, exact statistical values, and growth factor dosages. Functional behavioral recovery was not reported, and generated cells failed to achieve terminal dopaminergic or mature projection phenotypes.

Cited by